“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Saturday, August 30, 2025

Anacor Pharmaceuticals


Anacor Pharmaceuticals’ products

KERYDIN (tavaborole topical solution 5%)
Indication: Topical treatment of onychomycosis (toenail fungal infection)
Dose: Applied once daily to affected nails

Crisaborole topical ointment 2% (pipeline, later commercialized)
Indication: Atopic dermatitis (eczema) and potentially psoriasis
Status: Under development as a non-steroidal topical PDE-4 inhibitor

AN2690 (investigational, topical antifungal)
Indication: Onychomycosis and other fungal nail or skin infections
Status: Clinical development candidate (topical antifungal leveraging boron chemistry)

AN2728 (investigational, topical anti-inflammatory)
Indication: Psoriasis, also being evaluated for atopic dermatitis
Status: Clinical-stage pipeline asset (topical anti-inflammatory)

GSK ‘052 (formerly AN3365, systemic antibiotic)
Indication: Gram-negative bacterial infections (e.g., cUTI, cIAI, HAP/VAP)
Status: Licensed to GSK; systemic antibiotic candidate

AN2718 (investigational, topical antifungal)
Indication: Onychomycosis, skin fungal infections
Status: Clinical pipeline candidate

AN2898 (investigational, topical anti-inflammatory)
Indication: Psoriasis, atopic dermatitis
Status: Clinical pipeline candidate



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)